ARVN

Arvinas, Inc.

A biotech company pioneering a new kind of medicine that works like a cellular "molecular matchmaker": instead of blocking disease-causing proteins, its PROTAC drugs tag them for the cell's own garbage disposal (the proteasome) to shred and recycle. Founded in 2013 by Yale professor Craig Crews, Arvinas grew out of his earlier company Proteolix, and in 2026 its breast-cancer therapy vepdegestrant, developed with Pfizer, became the first FDA-approved PROTAC treatment. It focuses on cancer and neurological disease.

CUSIP: 04335A105HealthcareUS1 holder

Ownership Activity Financials Filings

ARVN

ARVN

Results of Operations and Financial Condition

Submission of Matters to a Vote of Security Holders

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Other Events

Regulation FD Disclosure

Entry into a Material Definitive Agreement

Results of Operations and Financial Condition

Regulation FD Disclosure